

identified for sale. However, land use applications may be considered after the sale if the parcel is not sold. The parcel may be subject to land use applications received prior to publication of this Notice if processing the application would have no adverse effect on the marketability of title, or the FMV of the parcel. Information concerning the sale, encumbrances of record, appraisals, reservations, procedures and conditions, CERCLA, and other environmental documents that may appear in the BLM public files for the proposed sale parcels are available for review during business hours, 7:30 a.m. to 4:30 p.m. Pacific Time, Monday through Friday, at the BLM Las Vegas Field Office, except during Federal holidays.

In order to determine the FMV through appraisal, certain extraordinary assumptions and hypothetical conditions may have been made concerning the attributes and limitations of the lands and potential effects of local regulations and policies on potential future land uses. Through publication of this Notice, the BLM advises that these assumptions may not be endorsed or approved by units of local government.

It is the buyer's responsibility to be aware of all applicable Federal, State, and local government laws, regulations and policies that may affect the subject lands, including any required dedication of lands for public uses. It is also the buyer's responsibility to be aware of existing or prospective uses of nearby properties. When conveyed out of Federal ownership, the lands will be subject to any applicable laws, regulations, and policies of the applicable local government for proposed future uses. It is the responsibility of the purchaser to be aware through due diligence of those laws, regulations, and policies, and to seek any required local approvals for future uses. Buyers should also make themselves aware of any Federal or State law or regulation that may impact the future use of the property. Any land lacking access from a public road or highway will be conveyed as such, and future access acquisition will be the responsibility of the buyer.

Any comments regarding the proposed sale will be reviewed by the BLM Nevada State Director or other authorized official of the Department of the Interior, who may sustain, vacate, or modify this realty action in response to such comments. In the absence of any comments, this realty action will become the final determination of the Department of the Interior.

**Authority:** 43 CFR 2711.1-2.

**Catrina Williams,**  
*Assistant Field Manager, Division of Lands.*  
[FR Doc. 2014-01759 Filed 1-28-14; 8:45 am]  
**BILLING CODE 4310-HC-P**

---

## INTERNATIONAL TRADE COMMISSION

[Corrected; Inv. No. 337-TA-906]

### Certain Standard Cell Libraries, Products Containing or Made Using the Same, Integrated Circuits Made Using the Same, and Products Containing Such Integrated Circuits; Institution of Investigation Pursuant to 19 U.S.C. 1337

**AGENCY:** U.S. International Trade Commission

**ACTION:** Correction of Institution of investigation pursuant to 19 U.S.C. 1337.

**SUMMARY:** Correction is made to the Scope of Investigation section. The date the Commission ordered action under the scope should be corrected from January 7, 2014 to January 17, 2014.

By order of the Commission.

Issued: January 24, 2014.

**Lisa R. Barton,**  
*Secretary to the Commission.*  
[FR Doc. 2014-01704 Filed 1-28-14; 8:45 am]  
**BILLING CODE 7020-02-P**

---

## INTERNATIONAL TRADE COMMISSION

[USITC SE-14-002]

### Sunshine Act Meetings

**AGENCY HOLDING THE MEETING:** United States International Trade Commission.

**TIME AND DATE:** January 31, 2014 at 11 a.m.

**PLACE:** Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205-2000.

**STATUS:** Open to the public.

**MATTERS TO BE CONSIDERED:**

1. Agendas for future meetings: none
2. Minutes
3. Ratification List
4. Vote in Inv. Nos. 701-TA-510 and 731-TA-1245 (Preliminary) (Calcium Hypochlorite from China). The Commission is currently scheduled to complete and file its determinations on February 3, 2014; views of the Commission are currently scheduled to be completed and filed on February 10, 2014.

5. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission:

Issued: January 23, 2014.

**William R. Bishop,**  
*Supervisory Hearings and Information Officer.*

[FR Doc. 2014-01819 Filed 1-27-14; 11:15 am]

**BILLING CODE 7020-02-P**

---

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration; Irix Manufacturing, Inc.

By Notice dated August 5, 2013, and published in the **Federal Register** on August 14, 2013, 78 FR 49546, IRIX Manufacturing, Inc., 309 Delaware Street, Greenville, South Carolina 29605, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance as API for clinical trials.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of IRIX Manufacturing, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated IRIX Manufacturing, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: January 15, 2014.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2014-01781 Filed 1-28-14; 8:45 am]

**BILLING CODE 4410-09-P**